Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

Watch all videos from ASCO GU 2023!

View all videos
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023

Bladder Cancer at ASCO GU 2023!

View all
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
4:38
Impact of neoadjuvant chemo on pathological staging and survival in sarcomatoid bladder cancer
Arya Mariam Roy • 18 Feb 2023
1:45
Results from dataset analysis of CDH1-mutated urothelial carcinoma patients
Andrea Necchi • 18 Feb 2023
1:18
Updates from KEYNOTE-905: immunotherapy + cystectomy vs cystectomy alone in MIBC
Andrea Necchi • 18 Feb 2023

Prostate Cancer at ASCO GU 2023!

View all
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023
1:01
Updates from ECHOS: real world outcomes from mCSPC treatment with docetaxel
Orazio Caffo • 17 Feb 2023
0:55
Post-progression therapies in patients with mCRPC progressing after docetaxel
Orazio Caffo • 17 Feb 2023
1:10
Challenges facing new pathway inhibitor treatments in prostate cancer
Kamal Sahu • 16 Feb 2023

Kidney Cancer at ASCO GU 2023!

View all
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
The content of VJOncology is intended for healthcare professionals